MitoTam brings new options for treatment of cancer and other diseases

The experimental drug MitoTam, which is the result of research by experts from the Institute of Biotechnology and which has been tested in the IPHYS CAS test facility, shows its potential. In the CPT we tested the safety of MitoTam after intravenous and oral administration to rats and we also examined the biodistribution of this drug in the plasma and selected tissues of rats and minipigs. Analytical method for the determination of MitoTam in the plasma of minipigs and in pig liver was developed and validated in CPT (Metabolomics Laboratory IPHYS CAS). Biodistribution findings provided very important information on drug accumulation in certain tissues and supported the results found in Phase 1 clinical trials.

Current information about MitoTam:

The Czech anti-cancer substance has an effect on type 2 diabetes

A new strategy for treating kidney cancer